Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has already been approved in the US, China, Japan, and other world markets for people with the early signs of Alzheimer's.

The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive decline was not large enough to outweigh the risk of serious brain swelling in patients.

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling.